Page last updated: 2024-09-03

gyki 53655 and s18986-1

gyki 53655 has been researched along with s18986-1 in 1 studies

Compound Research Comparison

Studies
(gyki 53655)
Trials
(gyki 53655)
Recent Studies (post-2010)
(gyki 53655)
Studies
(s18986-1)
Trials
(s18986-1)
Recent Studies (post-2010) (s18986-1)
1110221903

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Closier, M; Iop, F; Lestage, P; Lockhart, B1

Other Studies

1 other study(ies) available for gyki 53655 and s18986-1

ArticleYear
(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices.
    European journal of pharmacology, 2000, Aug-04, Volume: 401, Issue:2

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Benzodiazepines; Benzothiadiazines; Calcium; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Frontal Lobe; Hippocampus; In Vitro Techniques; Male; Norepinephrine; Pyrrolidinones; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Stereoisomerism; Tetrodotoxin; Tritium

2000